Cancer Gene Therapy

Telomerase Targeting with A Phosphorothioate Oligonucleotide

Published in Gene Therapy Weekly, September 8th, 1997

By using a phosphorothioate oligonucleotide (PS-ODN) that mimics the repeat sequence of the mammalian telomere, researchers were able inhibit telomerase activity in Burkitt's lymphoma cells in vitro and in vivo.

Telomeres, located at the ends of chromosomes, regulate cells' replicative capacities. Telomerase is a ribonucleoprotein that enzymatically synthesizes the 5'd-(TTAGGG)-3' repeat. It maintains or elongates telomere length in immortal and some somatic cells that would otherwise undergo cellular senescence (G.B. Morin et al., Cell 1989;59:521-9).

University of Nebraska researchers John E. Mata et al. developed a PS-ODN with a sequence...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry